Astrazeneca plc
NASDAQ: AZN
$63.85
-$2.42 (-3.7%)
Closing Price on November 6, 2024
AZN Articles
Development stage drug maker Targacept Inc. (NASDAQ: TRGT) is having its troubles these days. Earlier this month the company said it would not seek US Food and Drug Administration approval for its...
Published:
Increasing numbers of mutual funds have performances tied to huge investments in Apple (NASDAQ: AAPL). (Reuters) Tim Cook, Apple’s CEO, is in China to address production labor problems. (Reuters)...
Published:
We noted earlier today that AstraZeneca plc (NYSE: AZN) had lost a patent ruling and that the company’s anti-pyschotic drug Seroquel lost its patent protection today. That’s all it took for Teva...
Published:
Last Updated:
Late last Friday, drug maker AstraZeneca PLC (NYSE: AZN) lost its court fight to prevent a generic version of its anti-psychotic drug Seroquel from reaching the US market. The company had sought to...
Published:
Drug developer Targacept Inc. (NASDAQ: TRGT) and partner AstraZeneca plc (NYSE: AZN) today announced that they will not file for regulatory approval on an anti-depressant drug called TC-5214...
Published:
US equity markets opened lower this morning, but after the first hour or so of trading, the three major indexes moved to positive territory where they remained for the rest of the day. There was talk...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Tuesday morning. AON Corporation (NYSE: AON) Cut to Neutral at...
Published:
Last Updated:
Today is Facebook Day. It will be remembered that way as long as there are IPOs. The Facebook public offering has every aspect of what makes IPOs the focus of so much interest. No large medium in...
Published:
Dendreon (NASDAQ: DNDN) soared almost 40% in value, or $3.02 a share, in active trading on Thursday after announcing that fourth-quarter revenue from its Provenge prostate-cancer vaccine would exceed...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Thursday morning. AstraZeneca PLC (NYSE: AZN) Cut to...
Published:
Last Updated:
Layoffs were part of the business news yesterday. Enough people lost jobs in a series of three “downsizings” to reminds those who believe unemployment continues to fall that the economy still...
Published:
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like the movie business, a drug company tries to develop that...
Published:
Equities started the day with a solid move up, but lost momentum after about half an hour. The downward move lasted into the late morning, at which time stocks started a fitful climb back up. There...
Published:
Last Updated: